Characterization of a Salmonella sugar kinase essential for utilization of fructose-asparagine

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Biochemistry and Cell Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>bcb-2016-0138.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Note</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>27-Jul-2016</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Biswas, Pradip; The Ohio State University, Chemistry &amp; Biochemistry Behrman, Edward; The Ohio State University, Chemistry &amp; Biochemistry Gopalan, Venkat; The Ohio State University, Chemistry &amp; Biochemistry</td>
</tr>
<tr>
<td>Keyword:</td>
<td>Salmonella, Fructose-asparagine, Fructose-aspartate, Kinase, 6-Phosphofructose-Aspartate</td>
</tr>
</tbody>
</table>
Characterization of a *Salmonella* sugar kinase essential for utilization of fructose-asparagine

Pradip K. Biswas, Edward J. Behrman* and Venkat Gopalan*

Department of Chemistry & Biochemistry,

The Ohio State University, Columbus, OH 43210, USA

Correspondence: behrman.1@osu.edu or gopalan.5@osu.edu

Keywords: *Salmonella*, Fructose-Asparagine, Fructose-Aspartate,

6-Phosphofructose-Aspartate, Kinase
Abstract

Salmonella can utilize fructose-asparagine (F-Asn), a naturally occurring Amadori product, as its sole carbon and nitrogen source. Conversion of F-Asn to the common intermediates glucose-6-phosphate, aspartate, and ammonia was predicted to involve the sequential action of an asparaginase, a kinase and a deglycase. Mutants lacking the deglycase are highly attenuated in mouse models of intestinal inflammation due to the toxic build-up of the deglycase substrate. The limited distribution of this metabolic pathway in the animal gut microbiome raises the prospects for antibacterial discovery. We report the biochemical characterization of the kinase that was expected to transform fructose-aspartate to 6-phosphofructose-aspartate during F-Asn utilization. In addition to confirming its anticipated function, we determined through studies of fructose-aspartate analogues that this kinase exhibits a substrate-specificity with greater tolerance to changes to the amino acid (including the D-isomer of aspartate) than to the sugar.
**Introduction**

D-Fructose-L-asparagine (F-Asn) is an Amadori rearrangement product (Mossine and Mawhinney 2010) that occurs naturally in substantial quantities in foods, particularly after heating (Anet and Reynolds 1957; Eichner et al. 1994). *Salmonella enterica* serovar Typhimurium can utilize F-Asn as its sole carbon and nitrogen source (Ali et al. 2014; Sabag-Daigle et al. 2016). The *fra* locus in *Salmonella* is required for F-Asn utilization and consists of a gene encoding a transcriptional repressor (FraR) and the *fraBDAE* operon, which encodes a deglycase (FraB), kinase (FraD), transporter (FraA) and asparaginase (FraE). The functional roles for the structural genes in this operon were proposed based on the well-established pathway in *Escherichia coli* for utilization of D-fructose-L-lysine (F-Lys), another Amadori product (Wiame et al. 2002). Conversion of F-Asn to the common metabolic intermediates D-glucose-6-phosphate, L-aspartate and NH$_4^+$ was predicted to occur in three steps (**Fig. 1**).

Mutations in the *fraB* gene cause a severe attenuation in mouse models of inflammation (Ali et al. 2014). We recently showed that the *fraB* mutant accumulates the deglycase substrate (6-phosphofructose aspartate), and suggested that the toxicity associated with this sugar-phosphate buildup accounts for the attenuation in mice (Sabag-Daigle et al. 2016). In addition to *Salmonella*, genes in the *fra* locus appear to be present only in *Citrobacter* and *Clostridia*, indicating a limited presence in the animal gut microbiome. These findings make *fraB* an attractive target for future drug development, and motivate in-depth studies of the *fra* locus.

As part of our ongoing studies to characterize each of the gene products in the *fra* locus, we report here our investigations of the FraD kinase. Results from our experiments show that a recombinant FraD catalyzes the conversion of fructose-L-aspartate (F-Asp) to 6-phosphofructose aspartate (6-P-F-Asp), and that it exhibits a substrate-specificity that is more tolerant of changes to the amino acid than to the sugar.
Materials and Methods

Synthesis of Fructose-Aspartate and its analogues: Fructose-D-aspartate, fructose-L-glutamate, and tagatose-L-aspartate were made under the same conditions as those described for fructose-L-aspartate (Hansen and Behrman, 2016). Some modifications were required for the synthesis of fructose-L-cysteic acid, xylulose-L-aspartate and ribulose-L-aspartate. The fructose-L-cysteic acid reaction required longer heating: 17 h at 70°C followed by four more h at 80°C. Furthermore, fructose-L-cysteic acid was bound so weakly to Dowex-50 that it was eluted in the first few fractions by water alone, reminiscent of the behavior of 6-phosphofructose-L-aspartate (Hansen and Behrman 2016). The five carbon sugars, ribose and xylose, are much more reactive than glucose so that the reaction was carried out at 55°C for 16 h. The greater reactivity of the pentoses was reported nearly a hundred years ago (Maillard 1912), and recent studies provide a quantitation of this increased reactivity (Katchalsky and Sharon 1953; Laroque et al 2008; Sun et al. 2006).

We established the identity and purity of each of the analogs of D-fructose-L-aspartate by several approaches. First, the identity was checked by measurement of the exact mass [± 0.001 amu]. The MS spectra showed only trace amounts of the respective free amino acids. Second, proton NMR spectra gave the correct ratio of the upfield resonances due to the amino acid residue/the downfield resonances due to the sugar moiety and the α-proton of the amino acid. Integration revealed that impurities are <10%. Third, consistent with the MS data, paper electrophoresis and TLC with ninhydrin-based detection showed only traces of the free amino acid. [It is characteristic that the free amino acid reacts more rapidly with ninhydrin as compared to the Amadori products.] Fourth, the IR spectra are typical of Amadori products (Hansen and Behrman, 2016) and confirm the absence of major impurities. Finally, the specific rotations of D-fructose-L-aspartate and D-fructose-D-aspartate are -72 (Hansen and Behrman, 2016) and -4.5 (this study), respectively. The specific rotations of many fructose-amino acids have been
measured (Anet, 1957; Mossine et al. 1994; Walton et al. 1987). It is clear from these data that it is not possible to predict, even empirically, the rotations of the Amadori compounds based on those of the sugar and the amino acid components, although progress is being made in calculations for other compounds using density functional theory (Pardo et al. 2006). It suffices to say that the rotations of the diastereomeric D-fructose-aspartic acids are different.

Critical evidence for the absence of racemization during synthesis of D-fructose-D-aspartate came from the following observation: 6-Phospho-D-fructose-D-aspartate was made by heating D-glucose-6-phosphate with D-aspartate under the same conditions as those described for the synthesis of 6-phospho-D-fructose-L-aspartate (Hansen and Behrman, 2016). When this diastereomer was subjected to the action of a recombinant FraB, the deglycase in the F-Asn utilization pathway whose natural substrate is the L-aspartate diastereomer, the activity was 20-fold lower showing that no racemization of the D-aspartate moiety had occurred (Sengupta, Thomsen, Behrman and Gopalan, unpublished data).

Overexpression and purification of FraD: The FraD-encoding ORF was amplified by PCR using as template Salmonella genomic DNA and cloned into pET-33b (Novagen) using the InFusion HD cloning kit (Clontech). This construct (pET-33b-HT-FraD), which was kindly provided to us by Drs. Anice Sabag-Daigle and Brian Ahmer (Ohio State University), was designed to express FraD with an N-terminal His$_6$-affinity tag followed by a tobacco etch virus (TEV) protease cleavage site (GluAsnLeuTyrPheGlnSer).

*E. coli* Rosetta (DE3) cells were transformed with pET-33b-HT-FraD. A single colony was used to inoculate 5 ml of LB medium containing 35 μg/mL kanamycin (Kan) and 35 μg/mL chloramphenicol (Cam), and grown overnight at 37°C with shaking. The overnight culture was used to inoculate 500 mL of LB medium supplemented with Kan and Cam (as above). The cells were grown at 37°C with shaking (225 rpm) until OD$_{600}$ reached ~0.6 at which time the culture
was induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG). After IPTG addition, the cells were grown at 16°C for 20 h and harvested by centrifugation. The cell pellets were stored at -80°C.

For purification of FraD, which entailed immobilized metal-affinity and ion-exchange chromatography in tandem, we used the following buffers: Buffer A - 50 mM Tris-HCl (pH 7.5) and 500 mM NaCl; buffer B - 50 mM Tris-HCl pH- 7.5, 500 mM NaCl and 500 mM imidazole; lysis buffer - 50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 30 mM imidazole, 1 mM DTT, cOmplete mini-protease inhibitor cocktail tablet (Roche), 0.1 mM phenyl methyl sulphonyl fluoride (PMSF), 40 U DNase I (Roche) and 0.5 mg/ml lysozyme (Boehringer Mannheim); buffer W - 50 mM Tris-HCl (pH 7.5), 500 mM NaCl, 1 mM DTT and 0.1 mM PMSF; buffer C - 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM DTT and 0.1 mM PMSF; buffer D - 20 mM Tris-HCl (pH 7.5), 1 mM DTT and 0.1 mM PMSF; buffer E - 20 mM Tris-HCl (pH 7.5), 500 mM NaCl, 1 mM DTT and 0.1 mM PMSF; buffer F - 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM DTT, 10% (v/v) glycerol and 0.1 mM PMSF.

A cell pellet, obtained from a 500-mL overexpression culture, was thawed on ice, resuspended and sonicated in 25 mL of lysis buffer. After sonication, the crude lysate was centrifuged at 24,000 g for 40 min at 4°C. The supernatant was collected and filtered through a 0.22 μm syringe filter (Millipore) and applied to a 1-mL His-Trap HP column (GE Healthcare) that had been equilibrated with buffer W. After washing with 15 mL of buffer W, FraD was eluted using an AKTA FPLC (GE Healthcare) in three successive elution steps: 10-mL gradient from 50 to 250 mM imidazole, 2.5-mL gradient from 250 to 500 mM imidazole and 2.5 mL of 500 mM imidazole. FraD typically eluted between ~130 to 160 mM imidazole. Using SDS-PAGE and Coomassie Blue staining, fractions containing predominantly FraD were identified and pooled. To remove the His₆ tag, this pool was subjected to digestion with recombinant His₆-TEV protease, which was purified as described before (Tropea et al. 2009). The TEV protease
digestion (FraD:TEV, 20:1 molar ratio) was performed in a dialysis bag with one exchange against buffer C for 2 h at 30°C and then another overnight at 4°C. The dialyzed reaction mixture was then incubated with 0.2-mL cOmplete His-Tag purification resin (Roche) to remove His₆-FraD, His₆-tag (released from cleavage of His₆-FraD) and His₆-TEV protease. The flow-through, which was expected to contain FraD without the His₆ tag, was subjected to MALDI-ToF mass spectrometry to confirm TEV cleavage, and then dialyzed overnight against Buffer D.

As a final polishing step, the dialyzed FraD preparation (above) was loaded onto a 1-mL Q-Sepharose FF column (GE Healthcare) that been equilibrated with buffer D. After washing with 10 ml of buffer D, bound proteins were eluted using 10 mL of continuous gradient of buffer D and buffer E (0 to 500 mM NaCl). FraD typically eluted at ~200 mM NaCl. Fractions containing FraD were identified using SDS-PAGE and Coomassie Blue staining, and those exhibiting near homogeneity were pooled and dialyzed against buffer F at 4°C overnight. After dialysis, the concentration of FraD was calculated using its molar extinction coefficient (33,350 M⁻¹cm⁻¹) and A₂₈₀ value. Aliquots of the final preparation were stored at -80°C for later use.

FraD activity assays: FraD’s kinase activity was assayed in a 40-µL reaction mixture that contained 25 mM HEPES (pH 7.5), 25 mM KCl, 1 mM DTT, 5 mM MgCl₂, 1 mM ATP, 0.8 mM fructose-L-aspartate, 0.1 mg/mL BSA and 10 nM FraD (or as indicated in the text). Purified recombinant FraD was diluted in the assay buffer lacking the substrate and ATP. The standard assays were carried out at 37°C and at pH 7.5 for 30 min, with cleavage < 25% of the initial substrate concentration; to determine the pH and temperature optima, these parameters were varied as indicated. In all instances, blank reactions were set up using the same constituents except for the enzyme, and at the same pH and temperature as the test counterparts. The number of technical replicates for each experiment below is listed in the relevant section.
Because one of our objectives was to measure the FraD kinase activity with various substrate analogs of F-Asp, we chose a detection method that focused on ADP, a common product regardless of the Amadori substrate used in the assay. The ADP-Glo Kinase assay kit (Promega) measures ADP generated in a kinase-catalyzed reaction using a coupled assay that culminates in luminescence output. While the first step entails addition of an ADP-Glo reagent that effectively terminates the kinase reaction by depleting the unreacted ATP, the second detection reagent converts the remaining ADP to ATP and allows this newly synthesized ATP to be measured using a luciferase/luciferin reaction. The measured luminescence correlates with the amount of ADP generated in the kinase assay.

For the FraD assays, 5 µL of the assay was added to 5 µL of the ADP-Glo reagent, and the reaction mixture incubated at 22°C for 1 h. Subsequently, 10 µL of the detection reagent was added and incubated at 22°C for 1 h. The detection reagent was stored in dark and all steps containing this reagent were carried out in the dark. The 20-µL reaction was then transferred to 384 well-white flat bottom polystyrene microplates (Greiner Bio-One) and luminescence was measured using an Infinite M1000 PRO (TECAN) plate reader [instrument settings: integration time of 1000 msec; settle time of 300 msec, and no attenuation]. Blank readings were subtracted from the test readings to obtain the final luminescence. A standard curve was generated using relative light units (RLU) versus different concentrations of ADP (0.02 to 0.6 mM in assay buffer), and used as a reference for calculating ADP produced due to FraD activity. Blanks for the standard curve included all the buffer components except ADP.

To determine initial velocities, time-course analyses over four time points was performed. Conditions were chosen such that < 30% of the initial substrate concentration was cleaved at the last time point. Linear regression (Excel) analysis of ADP formed as a function of time was used to calculate the initial velocity ($r^2 \geq 0.96$).
Results

_Determining optimal assay conditions for FraD activity:_ Our first goal to characterize FraD was to obtain highly purified recombinant enzyme. After overexpression in _E. coli_, we were able to obtain nearly homogeneous FraD using sequential immobilized metal-affinity and ion-exchange chromatography (Fig. 2A). The purified enzyme was supplemented with 10% glycerol (v/v) and stored at -80°C in small aliquots. Once an aliquot was thawed for assays, it was not reused to minimize variability in activity on account of repeated freeze-thaw cycles. We observed that two cycles of freezing and thawing resulted in loss of activity for FraD up to 30% (data not shown).

Before proceeding to kinetic analyses and investigating substrate-recognition determinants, we first established the optimal pH and temperature for FraD activity. We used F-Asp (Behrman and Hansen 2016) to measure the FraD activity using the ADP-Glo kinase assay (see Methods). For these measurements, we performed 30-min end-point assays.

FraD kinase activity was tested at different pH values ranging from 4.2 to 9.8. We used three buffers to cover this pH range: pH 4.2 to 6.7 with 25 mM Bis-Tris, pH 6.7 to 8.8 with 25 mM HEPES, pH 8.8 to 9.8 with 25 mM CHES. To control for buffer-related variations, we included corrections at the overlap points by measuring activity at pH 6.7 using both Bis-Tris and HEPES, and at pH 8.8 using HEPES and CHES. Moreover, we confirmed that the readout from the ADP-Glo kinase assay itself was largely insensitive to the pH range tested (data not shown). These assays were conducted twice under identical conditions and the mean relative activity of FraD was plotted versus assay pH (Fig. 2B). Because all the buffers had been prepared at 22°C, the final plot (Fig. 2B) reflecting activity at 37°C includes corrections based on the ΔpKa/°C for each buffer. FraD activity is optimal between pH 7.3 to 8 (Fig. 2B), with the overall plot indicating the participation of at least two titratable groups in the catalytic mechanism.
FraD kinase activity was tested at different temperatures ranging from 4 to 80°C. To ensure temperature accuracy, assays were performed using a PCR thermocycler (PTC-100, MJ Research, Inc.) and 0.5-mL thin-walled tubes. These assays were conducted twice under identical conditions and the mean relative activity of FraD was plotted versus assay temperature (Fig. 2B). From this analysis, we determined the temperature optimum of 37°C for FraD activity.

We tested the ability of ATP, CTP, GTP and UTP to serve as the phosphoryl donor for the FraD-catalyzed reaction. The ADP-Glo assay, which is specific for measuring ADP, could not be used for this purpose. Instead, we employed a FraB + G6PDH-based coupled assay that we recently described (Sabag-Daigle et al. 2016). Results from these experiments indicated that ATP is greatly preferred over CTP, GTP or UTP (data not shown).

*Michaelis-Menten analysis of FraD activity:* By varying substrate concentrations 100-fold from 0.1 - 10 mM and using activities determined from end-point measurements, we established the anticipated saturable behavior. Michaelis-Menten curves were generated using Kaleidagraph (Synergy), and $K_m$ and $k_{cat}$ were determined to be $0.6 \pm 0.01$ mM and $5689 \pm 338$ min$^{-1}$, respectively (mean ± standard deviation from four trials; data not shown). The curve-fit errors for $K_m$ and $k_{cat}$ did not exceed 10% and 3%, respectively, in these trials ($r^2 \geq 0.98$). Subsequently, we measured the initial velocity at different substrate concentrations, and determined $K_m$ and $k_{cat}$ to be $0.77 \pm 0.08$ mM and $6364 \pm 180$ min$^{-1}$ (Fig. 3, left; curve-fit errors are listed and $r^2 = 0.99$); these parameters in turn yield a $k_{cat}/K_m = 8265$ min$^{-1}$mM$^{-1}$ (± 10% error).

*Substrate specificity of FraD:* Besides F-Asp, other Amadori compounds based upon modification in either the amino acid or sugar moiety were tested as potential FraD substrates to map the enzyme’s substrate-recognition determinants. Because we expected the substrates to be recognized and catalyzed differently, we empirically determined the optimal assay conditions for each by varying the time of incubation (up to 60 min) and or the concentration of FraD (from
4 to 100 nM). We tested all substrates at 5 mM, nearly ten-fold greater than the $K_m$ that we determined for FraD-catalyzed phosphorylation of F-Asp, and determined their initial velocities. Other than fructose-L-aspartate, we tested fructose-D-aspartate, fructose-L-glutamate (F-Glu), fructose-L-asparagine (F-Asn), fructose-L-cysteic acid (F-Cysteic), tagatose-L-aspartate, xylulose-L-aspartate and ribulose-L-aspartate (Fig. 4A). Each substrate was tested thrice under identical conditions and the mean relative activity (in percent) was plotted using F-Asp as the reference (Fig. 4B).

With regard to the amino acid, FraD was able to act on the four variants that we tested (F-Asp > F-Glu > F-Asn > F-Cysteic, all tested at 5 mM). Surprisingly, FraD acted with equal efficiency on both F-L-Asp and F-D-Asp, reflecting an unusual capacity to accept both stereoisomers. As far as the sugar is concerned, the tolerance to change is very small. Switching fructose to tagatose, its C4 epimer, resulted in nearly complete loss of activity. Replacing the ketohexose with two ketopentoses (xylulose or ribulose) resulted in at least a 1000-fold decrease in activity (Fig. 4B). Ribulose has the same chirality at carbons 3’ and 4’ carbons 4’ and 5’ in fructose while xylulose has the same chirality at carbons 3’ and 4’ as carbons 3’ and 4’ in fructose. When fructose was tested as a substrate, we did not detect any activity (data not shown).

To characterize the preference of FraD for F-L-Asp versus F-D-Asp, we performed Michaelis-Menten analysis with the latter. Using activities determined from end-point measurements with 0.1 to 10 mM F-D-Asp, $K_m$ and $k_{cat}$ were determined to be $1 \pm 0.05$ mM and 6508 ± 585 min$^{-1}$, respectively (mean ± standard deviation from three trials; data not shown). The curve-fit errors for $K_m$ and $k_{cat}$ did not exceed 11% and 4%, respectively, in these trials ($r^2 \geq 0.98$). Using initial velocity measurements in a separate exercise, we determined $K_m$ and $k_{cat}$ to be $0.94 \pm 0.07$ mM and 6380 ± 144 min$^{-1}$ (Fig. 3, right; curve-fit errors are listed and $r^2 = 0.99$); these parameters in turn yield a $k_{cat}/K_m = 6787$ min$^{-1}$mM$^{-1}$ (± 10% error).
Discussion

Although a three-step conversion was proposed for the catabolism of F-Asn (Fig. 1), there had been no biochemical characterization of the enzymes that catalyze these steps. Here, we demonstrate that FraD, the second enzyme in this pathway, indeed transforms F-Asp to 6-P-F-Asp. Our results are consistent with findings from a recent study where elimination of the FraB deglycase activity led to an accumulation of 6-P-F-Asp in Salmonella, suggesting that a kinase acts upstream of the deglycase (Sabag-Daigle et al. 2016). As the build-up of 6-P-F-Asp was shown to be associated with toxicity to Salmonella (Sabag-Daigle et al. 2016), it is important to understand the catalytic properties of this kinase.

Because the functional roles for the structural genes in the fra locus were predicted based on the E. coli frl operon that permits utilization of F-Lys (Wiame et al. 2002), it is instructive to compare the kinetic parameters of Salmonella FraD and E. coli FrlD, which converts F-Lys to 6-P-F-Lys. FrlD exhibits a $k_{cat}/K_M = 45,000 \text{ min}^{-1}\text{mM}^{-1}$ (Wiame et al. 2004; also, see Kojima et al. 2013), nearly five-fold greater than the 8265 min$^{-1}\text{mM}^{-1}$ that we determined for FraD (Fig. 3). YurL, the FrlD homolog in Bacillus subtilis, phosphorylates F-Lys with a $k_{cat}/K_M = 15 \text{ min}^{-1}\text{mM}^{-1}$ (Wiame et al. 2004). It is not possible to correlate these catalytic efficiencies with metabolic capabilities and fitness payoffs, especially since the activity reported for FrlD and YurL utilized ε-glycated lysine as opposed to the α-glycated F-Asp that we used to study FraD.

Even though FraD, FrlD and YurL differ with respect to primary amino acid sequence, substrate specificity, and catalytic efficiency, they share the common task of phosphorylating fructose-amines for subsequent bacterial catabolism (Deppe et al. 2011; Wiame et al. 2004). Both YurL and FrlD are known to phosphorylate a variety of fructose-amines (Wiame et al. 2004), mirroring our findings with FraD (Fig. 4). YurL preferred F-Val > F-Gly >> F-Lys (ε-glycated) (Wiame et al 2004), but FrlD exhibited the opposite trend: F-Lys (ε-glycated) >> F-Gly...
> F-Val. We observed that FraD prefers F-Asp > F-Glu > F-Asn > F-Cysteic (all of them α-
glycated). Overall, YurL, FrlD and FraD exhibit preferences for hydrophobic, basic and acidic
amino acid residues that are linked to fructose.

When we examined the importance of the sugar in facilitating substrate recognition by FraD,
it became evident that few changes are tolerated. Substitution of fructose in F-Asp with its C4
epimer led to nearly complete loss of activity, as was the replacement of fructose (a
ketohexose) with xylulose or ribulose (ketopentoses; Fig. 4B). Similar studies with sugar
analogues were not performed with FrlD/YurL, but FrlD (like FraD) also did not accept fructose
as a substrate (Wiame et al. 2002; see Conway and Voglmeir, 2016 for a review of sugar
kinases).

Since biocatalysts are generally highly stereospecific, it was surprising that FraD would act
with nearly equal efficiency with F-L-Asp and F-D-Asp (Fig. 3). There are a few precedents of
enzymes that fail to display strict chiral preferences (Calendar and Berg 1967; Nardi-Dei et al.
1997; Villiers and Hollfelder 2009). For example, B. subtilis tyrosyl-tRNA synthetase activates
both D- and L-tyrosine, although there appears to be kinetic discrimination; the $K_m$ for the D-Tyr
is four-fold lower than the L-Tyr, and the $k_{cat}$ for L-Tyr is 83-fold higher than D-Tyr (Calendar and
Berg 1967). In the case of the adenylation domain of tyrocidine synthetase (TycA), the enzyme
displayed only a two-fold stereoselectivity for L-Phe compared to D-Phe (Villiers and Hollfelder
2009). The ability of FraD to act on F-L-Asp and F-D-Asp with nearly equal $k_{cat}/K_m$ (Fig. 3)
mirrors TycA. Overall, these instances probably reflect the innate adaptive landscape of
enzymes that fosters selective growth advantages under specific conditions (Khersonsky and
Tawfik 2010), a testable premise. Importantly, our findings suggest that while FraD is rigid with
respect to recognition determinants in the sugar moiety, it is flexible with regard to the amino
acid (Fig. 4). We hope that ongoing crystallographic studies of FraD will provide a clear picture
of the latitude with respect to anchoring of the amino acid even while allowing an optimal
alignment of the active-site residues for phosphorylation of the C6-OH group in F-Asp. FraD joins the small family of enzymes that breach the expectation of exquisite stereospecificity during macromolecular recognition.

Acknowledgements

We are grateful to Jikang Wu [laboratory of Dr. Vicki Wysocki, Ohio State University (OSU)] for his kind assistance with mass spectrometry, which was used to ascertain the bona fides of the various Amadori products, Alex Bogard (OSU) for help with syntheses, Drs. Anice Sabag-Daigle and Brian Ahmer (OSU) for providing the FraD overexpression clone, Drs. Dmitri Kudryashov and Jennifer Ottesen (OSU) for generous consent to use their TECAN plate reader and MALDI-ToF, respectively, and Dr. Ahmer for comments on the manuscript. This work was supported by the National Institutes of Health (R01-AI116119 to EJB and VG).
REFERENCES


**Figure legends**

**Figure 1.** Proposed pathway for fructose-asparagine utilization in *Salmonella enterica*. 
**Figure 2.** Purity of recombinant *Salmonella* FraD and determination of optimal conditions for its activity. (A) SDS-PAGE [12% (w/v) polyacrylamide] analysis of the final FraD preparation obtained after overexpression in *E. coli* and a two-column purification. Lane 1, size markers; lane 2, 10 µg of the final preparation of FraD. (B) Assay pH (left) and temperature (right) were varied to determine the optimum for each variable. Standard assays conditions (10 nM FraD, 0.8 mM F-Asp, 30 min at 37°C) were employed to obtain these measurements. The relative activity of FraD was calculated at the different pH and temperatures using as reference the condition at which maximum activity was observed. The mean values were calculated using results from two independent experiments.

**Figure 3.** Michaelis–Menten analysis of recombinant FraD with F-L-Asp (left) and F-D-Asp (right). The *k*_cat and *K_m* values together with their respective curve-fit errors are listed (see text for additional supporting data).

**Figure 4.** Substrate specificity of FraD. (A) Structures of the different substrate analogues tested. (B) Relative activity (%) of each substrate analogue was calculated using as reference the initial velocity observed with F-L-Asp. All substrates (at 5 mM) were tested under standard assay conditions (pH 7.5, 37°C) to determine their respective initial velocity. Mean ± standard deviation values were calculated from three independent experiments.
Figure 2

A

kDa 1 2
15 20 25 30 35 40

B

Relative activity (%)

pH

Temperature (°C)

Figure 3

\[ K_{i} = 0.77 \pm 0.08 \text{ mM} \]
\[ k_{\text{cat}} = 6364 \pm 180 \text{ min}^{-1} \]

\[ K_{i} = 0.94 \pm 0.03 \text{ mM} \]
\[ k_{\text{cat}} = 6380 \pm 144 \text{ min}^{-1} \]
Figure 4

A

Fructose-L-Aspartate

Fructose-D-Aspartate

Fructose-L-Glutamate

Fructose-L-Cysteic Acid

Fructose-L-Asparagine

Tagatose-L-Aspartate

Ribulose-L-Aspartate

Xylulose-L-Aspartate

B

Relative activity (%) vs. Substrates

Relative activity (%)